Targets › EBNA1
5 programs from 4 companies in 7 trials: 6 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on EBNA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stanford University | VK-2019 EBNA1 DNA binding inhibitor | EBNA1 | Phase 2 | Nasopharyngeal Cancer | Jun 2027 |
| Baylor College of Medicine | EBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs) EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1 | LMP1, LMP2, BARF1, EBNA1 | Phase 1 | Hodgkin's Disease | Mar 2027 |
| ModernaTX | mRNA-1189 mRNA vaccine encoding Epstein-Barr virus antigens | EBNA1, LMP1, BZLF1 | Phase 1 | Epstein-Barr Virus Infection; Epstein-Barr Virus | May 2027 |
| Memorial Sloan Kettering Cancer Center | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19 | CD19, EBNA1, EBNA2, EBNA3 | Phase 1 | Acute Lymphocytic Leukemia | Sep 2027 |
| Baylor College of Medicine | MABEL CTLs EBV-specific cytotoxic T lymphocytes targeting LMP, BARF-1 and EBNA1 viral antigens | LMP1, BARF1, EBNA1 | Phase 1 | Hodgkin Disease | Mar 2029 |
Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Acute Lymphocytic Leukemia (1) Hodgkin Disease (1) Hodgkin's Disease (1) Nasopharyngeal Cancer (1)
other (3), mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.